trial
as of 2026-07-01A Study of Aripiprazole Lauroxil in Subjects With Schizophrenia or Schizoaffective Disorder
NCTId NCT02636842
at a glance
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 1
Status
Completed
Enrollment
47 (actual)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2015-12
Primary completion
2016-06
Eligibility
ALL · 18 Years · 65 Years
Interventions & indications
Sponsors
Alkermes, Inc.Lead Sponsor
Investigators
1
Robert Risinger, MDStudy Director
Sites
6 total
Cerritos, United StatesLemon Grove, United StatesOakland, United StatesHoffman Estates, United StatesMarlton, United StatesDallas, United States
Facts & assertions
4 sourced
Enrollment
47
Phase
PHASE1
Primary Completion Date
2016-06
Status
COMPLETED
relationships
The graph out of here
drug
drug
lead_sponsor
company
indication
investigator
person